8-K: Palvella Furnishes Q2 2025 Press Release and Investor Presentation

Q: What did Palvella Therapeutics (PVLA) disclose in the August 14, 2025 8-K?

The company announced it is furnishing a press release and an earnings presentation reporting financial results for the quarter ended June 30, 2025 and scheduled an earnings call on August 14, 2025 .

Q: Where can I find the press release and presentation referenced in the 8-K?

The press release is Exhibit 99.1 and the earnings presentation is Exhibit 99.2 to the 8-K filed on August 14, 2025 .

Q: How does the 8-K affect investor liability or incorporation into other filings?

Because the materials are furnished , they are not deemed "filed" under the Exchange Act and thus are not automatically incorporated by reference into other SEC filings.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. reported that on August 14, 2025 it announced financial results for the quarter ended June 30, 2025. The company furnished a press release and an earnings-call slide presentation as Exhibits 99.1 and 99.2 to this Current Report, and will hold an earnings call using the presentation on the same date. The filing explicitly states that the materials are being furnished rather than "filed," so they are not subject to the liabilities of Section 18 of the Exchange Act and are not automatically incorporated by reference into other SEC filings.

The report provides notice of the release and the investor presentation but does not include financial figures, results detail, or forward-looking guidance within the 8-K text itself; investors must consult the furnished press release and presentation for substantive financial information.

Positive

Timely disclosure of Q2 2025 results announcement and earnings call on August 14, 2025
Press release and investor presentation furnished as Exhibits 99.1 and 99.2, providing source materials for investors
Use of an earnings presentation alongside the call supports investor access to management commentary

Negative

No financial figures or metrics are included in the 8-K text, requiring review of exhibits for substantive data
Materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not automatically incorporated by reference

Insights

TL;DR: Routine 8-K furnishing Q2 results and slides; no financials included here, so market impact depends on the attached materials.

The filing performs a standard disclosure function: it furnishes a press release and earnings presentation and announces an earnings call on August 14, 2025. Because the documents are furnished rather than filed, they carry different legal treatment under the Exchange Act. The 8-K itself contains no numeric results or metrics, so immediate investor assessment must rely on Exhibit 99.1 and 99.2. Overall this is a procedural, neutral event unless the exhibits contain material surprises.

TL;DR: Clear, timely investor communication—press release and slides furnished for Q2 2025; lack of embedded figures in the 8-K limits standalone usefulness.

The company followed common practice by furnishing the press release and slide deck and scheduling an earnings call. This supports transparency and provides multiple channels for investors to obtain results. However, the 8-K's usefulness on its own is limited because it omits financial detail and directs readers to the exhibits. For engagement and compliance, the filing is appropriate; substantive analysis requires reviewing the attached materials.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

08/14/2025 - 07:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): August 14, 2025

    

Palvella Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Nevada	001-37471	30-0784346
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

125 Strafford Ave, Suite 360
Wayne, Pennsylvania		19087
(Address of principal executive offices)		(Zip Code)

     Registrant’s telephone number, including area code: (484) 253-1461

    

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

     Trading
Symbol(s)

     Name of each exchange on which registered

     Common Stock, $0.001 par value per share

     PVLA

     The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Palvella Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On August 14, 2025, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
99.1		Press Release of Palvella Therapeutics, Inc., dated August 14, 2025*
99.2		Earnings Call Presentation of Palvella Therapeutics, Inc., dated August 14, 2025*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Palvella Therapeutics, Inc.

Date:	August 14, 2025	By:	/s/ Matthew Korenberg
			Matthew Korenberg
			Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Palvella Therapeutics (PVLA) disclose in the August 14, 2025 8-K?

The company announced it is furnishing a press release and an earnings presentation reporting financial results for the quarter ended June 30, 2025 and scheduled an earnings call on August 14, 2025.

Are the press release and presentation in the 8-K filed or furnished?

Both Exhibit 99.1 (press release) and Exhibit 99.2 (presentation) are furnished, not filed, meaning they are not subject to Section 18 liabilities and are not incorporated by reference.

Does the 8-K include Palvella's Q2 2025 financial results or metrics?

No. The 8-K states the company announced results for the quarter ended June 30, 2025, but it does not include any financial figures; investors must review the furnished exhibits.

When is Palvella's earnings call scheduled?

The earnings call and related slide presentation are scheduled for August 14, 2025, the same date as the 8-K filing.

Where can I find the press release and presentation referenced in the 8-K?

The press release is Exhibit 99.1 and the earnings presentation is Exhibit 99.2 to the 8-K filed on August 14, 2025.

How does the 8-K affect investor liability or incorporation into other filings?

Because the materials are furnished, they are not deemed "filed" under the Exchange Act and thus are not automatically incorporated by reference into other SEC filings.